Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs